MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598611 | Name: Lercanidipine, (S)-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lercanidipine, (S)- is an antihypertensive (blood pressure lowering) drug.

Chemical Structure

Lercanidipine, (S)-
Lercanidipine, (S)-
CAS#185197-71-1

Theoretical Analysis

MedKoo Cat#: 598611

Name: Lercanidipine, (S)-

CAS#: 185197-71-1

Chemical Formula: C36H41N3O6

Exact Mass: 611.2995

Molecular Weight: 611.73

Elemental Analysis: C, 70.68; H, 6.76; N, 6.87; O, 15.69

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Lercanidipine, (S)-; (S)-Lercanidipine; (+)-Lercanidipine;
IUPAC/Chemical Name
3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl (S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
InChi Key
ZDXUKAKRHYTAKV-XIFFEERXSA-N
InChi Code
InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3/t33-/m0/s1
SMILES Code
O=C(C1=C(C)NC(C)=C(C(OC)=O)[C@@H]1C2=CC=CC([N+]([O-])=O)=C2)OC(C)(C)CN(CCC(C3=CC=CC=C3)C4=CC=CC=C4)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 611.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Derosa G, Bonaventura A, Romano D, Bianchi L, Fogari E, D'Angelo A, Maffioli P. Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study. J Am Soc Hypertens. 2014 Jun;8(6):422-8. doi: 10.1016/j.jash.2014.03.329. Epub 2014 Apr 4. PubMed PMID: 24836352. 2: Derosa G, Bonaventura A, Romano D, Bianchi L, Fogari E, D'Angelo A, Maffioli P. Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients. J Clin Pharm Ther. 2014 Jun;39(3):277-85. doi: 10.1111/jcpt.12139. Epub 2014 Mar 17. PubMed PMID: 24635387. 3: Wu Y, Xu M, Wang H, Xu X, Zhao S, Zhang M, Jin H, Yan J, Wang B, Gong J, Lu X, Peng J, Dai Q. Lercanidipine hydrochloride versus felodipine sustained-release for mild-to-moderate hypertension: a multi-center, randomized clinical trial. Curr Med Res Opin. 2015 Jan;31(1):171-6. doi: 10.1185/03007995.2014.960073. Epub 2014 Nov 26. PubMed PMID: 25425015. 4: Ha ES, Choo GH, Baek IH, Kim JS, Cho W, Jung YS, Jin SE, Hwang SJ, Kim MS. Dissolution and bioavailability of lercanidipine-hydroxypropylmethyl cellulose nanoparticles with surfactant. Int J Biol Macromol. 2015 Jan;72:218-22. doi: 10.1016/j.ijbiomac.2014.08.017. Epub 2014 Aug 23. PubMed PMID: 25159878. 5: Yang Z. Efficacy and safety evaluation of perindopril-lercanidipine combined therapy in patients with mild essential hypertension. Curr Med Res Opin. 2015 Jan;31(1):183-6. doi: 10.1185/03007995.2014.960072. Epub 2014 Nov 26. PubMed PMID: 25424689. 6: Derosa G, Mugellini A, Querci F, Franzetti I, Pesce RM, D'Angelo A, Maffioli P. Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. Sci Rep. 2015 Aug 5;5:12603. doi: 10.1038/srep12603. PubMed PMID: 26243165; PubMed Central PMCID: PMC4525144. 7: Gosteva EV, Vasil'eva LV. [Effect of Fixed Lercanidipine/Enalapril Combination on 24-Hour Blood Pressure Proffie in Elderly Patients With Arterial Hypertension]. Kardiologiia. 2015;55(2):32-6. Russian. PubMed PMID: 26164986. 8: Xu M, Wu Y, Wang H, Xu X, Zhao S, Zhang M, Jin H, Yan J, Wang B, Gong J, Lu X, Peng J, Dai Q. Effects of lercanidipine hydrochloride versus felodipine sustained-release on day-to-day home blood pressure variability. Curr Med Res Opin. 2016 Oct;32(sup2):43-52. PubMed PMID: 27779454. 9: Zanchetti A. Lercanidipine in worldwide usage. Curr Med Res Opin. 2015 Jan;31(1):161-2. doi: 10.1185/03007995.2014.986717. Epub 2014 Nov 26. PubMed PMID: 25425127. 10: Maldonado J, Pereira T, Tavares A. Efficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in Portugal. Drugs R D. 2014 Jun;14(2):147-54. doi: 10.1007/s40268-014-0046-8. PubMed PMID: 24831818; PubMed Central PMCID: PMC4070459. 11: Robles NR, Calvo C, Sobrino J, Espinel E, Esteban R, Mateos L, Macias JF. Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. Curr Med Res Opin. 2016 Oct;32(sup2):29-34. PubMed PMID: 27779460. 12: Peixiao S, Ningyuan F, Haiya W. Lercanidipine effect on circulating CD34+ progenitor cells in elderly patients: a randomized study. Curr Med Res Opin. 2016 Oct;32(sup2):9-12. PubMed PMID: 27779456. 13: Rizzoni D. Fixed-dose lercanidipine and enalapril in field practice: a meta-analysis. Curr Med Res Opin. 2016 Oct;32(sup2):13-15. PubMed PMID: 27779457. 14: Álvarez C, Gómez E, Simón M, Govantes C, Guerra P, Frías J, García-Arieta A. Differences in lercanidipine systemic exposure when administered according to labelling: in fasting state and 15 minutes before food intake. Eur J Clin Pharmacol. 2012 Jul;68(7):1043-7. doi: 10.1007/s00228-012-1215-8. Epub 2012 Feb 1. PubMed PMID: 22294059. 15: Rizzoni D. Dose-response effect of the lercanidipine/enalapril combination: a pooled analysis. Curr Med Res Opin. 2016 Oct;32(sup2):17-23. PubMed PMID: 27779458. 16: Derosa G, Mugellini A, Pesce RM, D'Angelo A, Maffioli P. Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. BMC Cardiovasc Disord. 2016 Apr 12;16:66. doi: 10.1186/s12872-016-0237-z. PubMed PMID: 27068332; PubMed Central PMCID: PMC4828780. 17: Parati G. Vascular effects of the lercanidipine/enalapril combination: clinical relevance. Curr Med Res Opin. 2016 Oct;32(sup2):25-28. PubMed PMID: 27779459. 18: Cicero AF, Gerocarni B, Rosticci M, Borghi C. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens. 2012;34(2):113-7. doi: 10.3109/10641963.2011.601381. Epub 2011 Oct 3. PubMed PMID: 21967031. 19: Yeh JL, Hsu JH, Liang JC, Chen IJ, Liou SF. Lercanidipine and labedipinedilol--A attenuate lipopolysaccharide/interferon-γ-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities. Atherosclerosis. 2013 Feb;226(2):364-72. doi: 10.1016/j.atherosclerosis.2012.12.005. Epub 2012 Dec 25. PubMed PMID: 23290263. 20: Chen T, Chen GH, Yang TS, Zhong ZY, An WS, Zhang XX, Li JD. Efficacy and safety of the treatment: combination of benazepril/lercanidipine vs. benazepril alone in patients with mild-to-moderate hypertension. Chin Med J (Engl). 2013 Jun;126(12):2286-90. PubMed PMID: 23786940.